Insights Investing

Prem Watsa’s Q3 2026 13F Portfolio Analysis: Fairfax Financial Holdings’ Strategic Shifts

12 min read EN繁體

Podcast · Listen (13 min)

Prem Watsa Swaps Orla for Equinox Gold: 24.5% of Portfolio | Investor Playbook

In brief

DeepValues Research, “Prem Watsa’s Q3 2026 13F Portfolio Analysis: Fairfax Financial Holdings’ Strategic Shifts” (Nov 20, 2026): During the third quarter of 2026 (ended September 30, 2026), Fairfax Financial Holdings executed a major portfolio transformation within its US long equity holdings, dominated by a massive capital reallocation within the precious metals sector.

Source: https://research.deepvalues.ai/insights/2026-11-20-prem-watsa-q3-2026-13f-portfolio-research/ · Markdown

Contents
  1. The Investor: Philosophy, Fund, and Lifetime Work
  2. The Portfolio at Quarter End: Size, Concentration, and Core Holdings
  3. Fairfax Financial Holdings Core Holdings (Q3 2026)
  4. What Changed: New, Added, Trimmed, and Sold-Out Positions
  5. The Biggest Moves, Valued
  6. 1. Coty Inc. (COTY) — New Position Analysis
  7. 2. Johnson & Johnson (JNJ) — Liquidated Position Analysis
  8. 3. Molson Coors Beverage Company (TAP) — Expanded Position Analysis
  9. Track Record: The Ten-Year 13F Clone Against the S&P 500
  10. 10-Year Performance Summary (2016-11-21 to 2026-11-20 / 41 Filings)
  11. Historical Annual Returns Breakdown
  12. Analytical Context & Clone Limitations
  13. What a Patient Investor Can Learn
  14. Key Numbers

During the third quarter of 2026 (ended September 30, 2026), Fairfax Financial Holdings executed a major portfolio transformation within its US long equity holdings, dominated by a massive capital reallocation within the precious metals sector. Chairman and CEO Prem Watsa completely liquidated Fairfax's position in Orla Mining Ltd. ($568.5 million sold out) and redeployed that capital into a new anchor position in Equinox Gold Corp., acquiring $649.1 million worth of shares. Accounting for 24.5% of the total reported portfolio value at quarter-end, this single transaction represents the largest capital deployment of the period, fundamentally reshaping the concentration profile of Fairfax’s reported US equity holdings and driving overall portfolio turnover.

The Investor: Philosophy, Fund, and Lifetime Work#

This portfolio analysis focuses on the public US equity disclosures of Fairfax Financial Holdings (CIK: 0000915191; SEC Form 13F-HR accession number 0001104659-26-127473, filed November 16, 2026). Under the leadership of Prem Watsa, often referred to as "Canada's Warren Buffett," Fairfax Financial Holdings employs a classic value investing methodology. This investment philosophy is characterized by high portfolio concentration, multi-year holding horizons, a deep focus on balance-sheet strength, and a persistent willingness to execute contrarian capital reallocations into out-of-favor or capital-intensive industries.

In strict adherence to institutional research standards, this report evaluates only the Form 13F long equity filings of Fairfax Financial Holdings. Non-US primary listings, fixed-income holdings, cash reserves, derivative structures, and private corporate investments held outside of direct Form 13F reporting are excluded from this quantitative baseline. No external investment funds or non-Fairfax entities are cited or benchmarked in this analysis.

The Portfolio at Quarter End: Size, Concentration, and Core Holdings#

As of September 30, 2026, Fairfax Financial Holdings reported a total US long equity portfolio value of $2.65 billion spread across 34 positions. This reflects a subtle expansion in total market value compared to the $2.64 billion across 32 positions reported in Q2 2026.

The portfolio exhibits extreme conviction, with the top ten holdings accounting for 89.7% of total reported US equity capital. Mining and precious metals allocations dominate the upper tier, complemented by major positions in consumer staples, retail healthcare, basic apparel, and structural steel manufacturing.

Fairfax Financial Holdings Core Holdings (Q3 2026)#

Ticker Company Name Value ($M) % of Portfolio Change in Shares
EQX Equinox Gold Corp. $649.1M 24.5% New
EGO Eldorado Gold Corp /FI $526.7M 19.9% Unchanged
KHC Kraft Heinz Co $325.0M 12.3% Unchanged
CVS CVS Health Corporation $232.4M 8.8% Unchanged
UAA Under Armour, Inc. $202.3M 7.6% Unchanged
CLF Cleveland-Cliffs Inc. $164.2M 6.2% Unchanged
UA Under Armour, Inc. (Class C) $95.7M 3.6% Unchanged
TAP Molson Coors Beverage Company $83.7M 3.2% +15%
WEN The Wendy’s Company $51.1M 1.9% Unchanged
ATS ATS Corp $44.9M 1.7% Unchanged
HP Helmerich & Payne, Inc. $43.2M 1.6% -1%
TSM Taiwan Semiconductor Manufacturing Co. $42.8M 1.6% Unchanged
PFE Pfizer Inc $40.4M 1.5% +36%
BNS Bank of Nova Scotia $32.7M 1.2% Unchanged
GM General Motors Co $28.9M 1.1% Unchanged

What Changed: New, Added, Trimmed, and Sold-Out Positions#

Fairfax Financial Holdings engaged in $699.3 million in total purchases and $589.7 million in total sales during Q3 2026 (calculated using quarter-end closing prices). Portfolio activity remained balanced between capital deployment and harvesting, generating a quarterly turnover rate of approximately 22.3%. In total, the filing detailed 6 new positions, 3 share additions, 2 position trims, and 4 complete liquidations.

The quarterly transactions are ranked below in descending order of absolute estimated dollar magnitude:

  1. Equinox Gold Corp. (EQX) * Action: New Position * Quarter-End Value: $649.1M (24.5% of portfolio) * Inferred Motive: Major intra-sector reallocation within precious metals, establishing an immediate top anchor holding.
  2. Orla Mining Ltd. (ORLA) * Action: Sold-Out Completely * Prior Quarter Value: ~$568.5M * Inferred Motive: Full capital recycling designed to fund the acquisition of Equinox Gold Corp.
  3. Coty Inc. (COTY) * Action: New Position * Quarter-End Value: $20.0M (0.8% of portfolio) * Inferred Motive: Opportunistic positioning in a discounted consumer beauty company exhibiting steady underlying owner-earnings generation.
  4. Johnson & Johnson (JNJ) * Action: Sold-Out Completely * Prior Quarter Value: ~$18.6M * Inferred Motive: Liquidation of an overvalued defensive holding where public market pricing significantly exceeded fundamental intrinsic value.
  5. Molson Coors Beverage Company (TAP) * Action: Added (+15% share count) * Quarter-End Value: $83.7M (3.2% of portfolio; ~$10.9M capital deployment) * Inferred Motive: Accumulation of an undervalued consumer staple trading at a measurable discount to owner-earnings intrinsic value.
  6. Pfizer Inc. (PFE) * Action: Added (+36% share count) * Quarter-End Value: $40.4M (1.5% of portfolio; ~$10.6M capital deployment) * Inferred Motive: Value-oriented accumulation in a high-yielding, large-cap pharmaceutical enterprise with durable operating cash flows.
  7. Uber Technologies, Inc. (UBER) * Action: New Position * Quarter-End Value: $2.5M (0.1% of portfolio) * Inferred Motive: Small starter allocation into a platform entity demonstrating expanding operating leverage.
  8. International Money Express, Inc. (IMXI) * Action: New Position * Quarter-End Value: $2.4M (0.1% of portfolio) * Inferred Motive: Niche financial services entry at modest cash-flow valuation multiples.
  9. Canadian National Railway Company (CNI) * Action: Trimmed (-20% share count) * Quarter-End Value: $2.4M (0.1% of portfolio; ~$595,527 share trim) * Inferred Motive: Incremental profit harvesting and capital rebalancing.
  10. Sunbelt Rentals Holdings, Inc. (SUNB)
    • Action: New Position
    • Quarter-End Value: $2.3M (0.1% of portfolio)
    • Inferred Motive: Strategic entry into industrial capital equipment rental assets.
  11. Gildan Activewear Inc. (GIL)
    • Action: New Position
    • Quarter-End Value: $1.2M (0.1% of portfolio)
    • Inferred Motive: Incremental value allocation in basic apparel manufacturing.
  12. Brightstar Lottery PLC (BRSL)
    • Action: Added (+61% share count)
    • Quarter-End Value: $1.1M (0.0% of portfolio; ~$418,000 capital deployment)
    • Inferred Motive: Expansion of a micro-cap holding displaying high cash yields.
  13. Electronic Arts Inc. (EA)
    • Action: Sold-Out Completely
    • Prior Quarter Value: ~$1.0M
    • Inferred Motive: Complete exit and reallocation of non-core interactive media holdings.
  14. Cementos Pacasmayo SAA (CPAC)
    • Action: Sold-Out Completely
    • Prior Quarter Value: ~$594,500
    • Inferred Motive: Liquidation of minor regional materials exposure.
  15. Helmerich & Payne, Inc. (HP)
    • Action: Trimmed (-1% share count)
    • Quarter-End Value: $43.2M (1.6% of portfolio; ~$373,220 share trim)
    • Inferred Motive: Minor portfolio rebalancing of energy services exposure.

The Biggest Moves, Valued#

To establish whether Prem Watsa’s allocation decisions acquired stock at prices below underlying worth or exited positions above intrinsic value, DeepValues Research conducts double-verified Discounted Cash Flow (DCF) and Reverse DCF valuation modeling. These models process ten years of SEC XBRL data (Form 10-K and 10-Q filings) using Warren Buffett’s owner-earnings framework (Owner Earnings = Operating Cash Flow - Maintenance Capex - Stock-Based Compensation). Maintenance capex is defined as the smaller of total capital expenditures and reported depreciation & amortization.

Below is the forensic valuation breakdown of three key transactions executed during the quarter: Coty Inc. (new allocation), Johnson & Johnson (complete liquidation), and Molson Coors Beverage Company (position expansion).


1. Coty Inc. (COTY) — New Position Analysis#

Fairfax initiated a $20.0 million position in Coty Inc., representing 0.8% of reported equity. DeepValues completed a double-verified cash flow analysis spanning fiscal years 2017 through 2026, including the Trailing Twelve Month (TTM) period ended September 30, 2026.

Owner Earnings Fundamentals#

Coty’s decade-long cash flow history reveals structural operational restructurings and top-line volatility. Revenues contracted from $7.7 billion in FY 2017 down to $4.6 billion in FY 2021, before recovering and stabilizing between $5.3 billion and $6.1 billion over the FY 2022 to FY 2026 window.

  • Net Income vs. Cash Flow Divergence: Across the ten-year period, Coty recorded substantial net losses (such as -$3.8 billion in FY 2019 and -$0.6 billion in TTM 2026), primarily driven by non-cash impairment charges and depreciation ($0.4 billion to $0.7 billion annually).
  • Cash Generation: Operating cash flow remained consistently positive across nearly all periods, hovering between $0.4 billion and $0.7 billion. Capital expenditures stabilized at $0.2 billion annually post-FY 2021.
  • TTM Figures (ended Sept 30, 2026): Revenue stood at $5.8 billion; Net Income at -$0.6 billion; Operating Cash Flow reached $0.6 billion. Capital Expenditures were $0.2 billion against D&A of $0.5 billion. Stock-based compensation was negligible ($0.0 billion).
  • TTM Owner Earnings: Calculated at $0.4 billion ($0.6B OCF - $0.2B maintenance capex).

DCF Intrinsic Valuation Scenarios#

  • Market Price (as of Nov 20, 2026): $3.93 per share
  • Discount Rate: 10.0% | Net Debt: -$2.5 billion ($0.2B cash less $2.7B debt) | Shares: 0.881 billion

  • Conservative Case ($2.41 Intrinsic Value): Assumes 5-year owner earnings growth ($g$) of 0.4%, fading to 2.5% terminal growth. The market price is 63.1% above conservative intrinsic value.

  • Base Case ($2.54 Intrinsic Value): Assumes 5-year growth ($g$) of 0.9% (reflecting the 10-year historical owner-earnings CAGR derived from 3-year averages), fading to 2.5% terminal growth. Margin of Safety: -54.8% (Market price is 54.8% above base intrinsic value).
  • Optimistic Case ($3.88 Intrinsic Value): Assumes 5-year growth ($g$) of 4.9%, fading to 2.5% terminal growth. The market price is 1.3% above optimistic intrinsic value.

Reverse DCF & Implied Growth Rates#

At $3.93 per share (market capitalization of $3.5 billion), a Reverse DCF indicates that public markets are pricing in owner earnings growth of 5.0% annually over the next 5 years (fading to 2.5% at a 10.0% discount rate). This market growth expectation is significantly higher than Coty's actual 10-year owner-earnings growth rate of 0.9%.

Strategic Evaluation#

Prem Watsa initiated a position in Coty Inc. at $3.93 per share. Based on DeepValues owner-earnings modeling, Watsa acquired shares above estimated base intrinsic value ($2.54 per share), accepting a negative margin of safety under long-term historical cash flow trends.


2. Johnson & Johnson (JNJ) — Liquidated Position Analysis#

Fairfax completely exited its $18.6 million holding in Johnson & Johnson. JNJ represents a classic defensive franchise characterized by smooth, expanding operating cash flow generation over the ten-year evaluation window.

Owner Earnings Fundamentals#

Between FY 2017 and TTM September 2026, Johnson & Johnson systematically grew top-line revenue from $71.9 billion to $99.3 billion. Operating cash flow expanded from $18.8 billion in FY 2017 to $26.2 billion in TTM 2026.

  • Capital Intensity: Capital expenditures ranged between $3.2 billion and $5.6 billion annually, consistently below reported depreciation & amortization ($3.8 billion to $8.1 billion), establishing total capex as maintenance spending.
  • TTM Figures (ended Sept 27, 2026): Revenue reached $99.3 billion; Net Income registered $16.1 billion; Operating Cash Flow totaled $26.2 billion. Capital Expenditures were $5.6 billion; Stock-Based Compensation was $1.4 billion.
  • TTM Owner Earnings: Calculated at $19.2 billion ($26.2B OCF - $5.6B maintenance capex - $1.4B stock comp).

DCF Intrinsic Valuation Scenarios#

  • Market Price (as of Nov 20, 2026): $270.61 per share
  • Discount Rate: 10.0% | Net Debt: -$27.4 billion ($17.2B cash less $44.7B debt) | Shares: 2.407 billion

  • Conservative Case ($87.94 Intrinsic Value): Assumes 5-year growth ($g$) of 0.9%. The market price is 207.7% above conservative intrinsic value.

  • Base Case ($92.79 Intrinsic Value): Assumes 5-year growth ($g$) of 1.7% (10-year historical owner-earnings CAGR), fading to 2.5% terminal growth. Margin of Safety: -191.7% (Market price is 191.7% above base intrinsic value).
  • Optimistic Case ($118.54 Intrinsic Value): Assumes 5-year growth ($g$) of 5.7%. The market price is 128.3% above optimistic intrinsic value.

Reverse DCF & Implied Growth Rates#

At $270.61 per share (market valuation of $651.4 billion), the market implies that JNJ will expand owner earnings at 20.1% annually over the next 5 years. This requirement stands in sharp contrast to JNJ's actual 10-year historical owner-earnings CAGR of 1.7%.

Strategic Evaluation#

Prem Watsa completely liquidated Johnson & Johnson at $270.61 per share, selling significantly above base intrinsic value ($92.79 per share). This trade aligns with DeepValues Intelligence coverage of JNJ. In the October 13, 2026 report, DeepValues issued a Neutral stance (3.08/5) with the market price at $264 against a headline intrinsic value of $184, highlighting substantial market overvaluation relative to fundamental cash flows.


3. Molson Coors Beverage Company (TAP) — Expanded Position Analysis#

Fairfax increased its share holdings in Molson Coors Beverage Company by 15% (~$10.9 million purchase), building its allocation to $83.7 million (3.2% of reported portfolio value).

Owner Earnings Fundamentals#

Molson Coors displays traditional staple cash flow dynamics, with top-line revenue oscillating between $11.7 billion (FY 2020 pandemic low) and $13.9 billion (FY 2023 peak), settling at $12.9 billion in TTM 2026.

  • Earnings vs. Cash Flow Volatility: Net income experienced sharp swings due to non-cash asset impairment charges (such as -$2.1 billion in FY 2025). However, operating cash flow remained steady between $1.5 billion and $2.3 billion throughout the decade.
  • TTM Figures (ended Sept 30, 2026): Revenue stood at $12.9 billion; Net Income was $0.9 billion; Operating Cash Flow registered $1.8 billion. Capital Expenditures were $0.7 billion against D&A of $0.7 billion. Stock-based compensation was $0.0 billion.
  • TTM Owner Earnings: Derived at $1.1 billion ($1.8B OCF - $0.7B maintenance capex).

DCF Intrinsic Valuation Scenarios#

  • Market Price (as of Nov 20, 2026): $39.65 per share
  • Discount Rate: 10.0% | Net Debt: -$5.1 billion ($0.6B cash less $5.7B debt) | Shares: 0.185 billion

  • Conservative Case ($45.49 Intrinsic Value): Assumes 5-year growth ($g$) of 0.0%. Margin of Safety: 12.8%.

  • Base Case ($45.49 Intrinsic Value): Assumes 5-year growth ($g$) of 0.0% (reflecting the 10-year historical owner-earnings CAGR of 0.0%). Margin of Safety: 12.8%.
  • Optimistic Case ($63.57 Intrinsic Value): Assumes 5-year growth ($g$) of 4.0%. Margin of Safety: 37.6%.

Reverse DCF & Implied Growth Rates#

At $39.65 per share (market valuation of $7.3 billion), the market implies a contraction in owner earnings of -1.5% per year over the next 5 years before fading to 2.5% terminal growth. This pricing reflects overly pessimistic market expectations relative to the firm's flat 0.0% historical baseline.

Strategic Evaluation#

Prem Watsa expanded Fairfax’s stake in Molson Coors at $39.65 per share, purchasing shares below estimated base intrinsic value ($45.49 per share) and successfully capturing a 12.8% margin of safety.

Track Record: The Ten-Year 13F Clone Against the S&P 500#

To measure the standalone equity selection capability of Fairfax Financial Holdings' public disclosures, DeepValues evaluates a simulated 13F Clone Portfolio. The clone model purchases each quarterly 13F common-stock holding, weighted by reported value, at the market close on the first trading day following the SEC filing deadline. Holdings are rebalanced quarterly upon subsequent disclosures, with dividend-adjusted total returns benchmarked against the S&P 500 ETF (SPY).

10-Year Performance Summary (2016-11-21 to 2026-11-20 / 41 Filings)#

  • Fairfax 13F Clone CAGR: 1.5%
  • SPY Benchmark CAGR: 13.9%
  • Annualized Performance Differential: -12.4 percentage points
  • Fairfax Clone Cumulative Total Return: +16.3%
  • SPY Benchmark Cumulative Total Return: +267.6%
  • Maximum Drawdown (Month-End): Fairfax Clone -63.1% vs. SPY -23.9%
  • Portfolio Extremes: Best year was 2021 (+44.8% vs. SPY +28.7%); worst year was 2018 (-33.7% vs. SPY -4.6%).

Historical Annual Returns Breakdown#

Year Fairfax Clone Return SPY Return
2016* -3.9% +2.1%
2017 +31.4% +21.7%
2018 -33.7% -4.6%
2019 -4.9% +31.2%
2020 +5.9% +18.3%
2021 +44.8% +28.7%
2022 -33.0% -18.2%
2023 +18.7% +26.2%
2024 +9.9% +24.9%
2025 +11.1% +17.7%
2026* -1.9% +2.1%

*Partial year figures.

Analytical Context & Clone Limitations#

The simulated 13F clone underperformed the broad US market benchmark by -12.4 percentage points annually over the 10-year tracking window. Structural analytical factors explain this performance discrepancy:

  1. Pricing Coverage Constraints: Over the 10-year historical window, public pricing coverage averaged only 48.6% of total reported portfolio value. Non-US primary listings (such as primary Toronto Stock Exchange equities) and unpriced security identifiers were excluded and remaining positions reweighted, creating a partial tracking sample.
  2. Exclusion of Core Balance Sheet Assets: Form 13F filings omit short positions, cash equivalents, fixed-income portfolios, credit holdings, derivative hedges, and non-US listed equities. For an insurance conglomerate like Fairfax Financial Holdings, net float management, bond yields, macro hedging strategies, and private subsidiary earnings generate a significant portion of total corporate economic value creation that standard 13F long equity tracking cannot capture.
  3. Information Lag and Intraday Trading: Public disclosures occur up to 45 days after quarter-end, ignoring intraday executions, intra-quarter adjustments, or rapid capital reallocations executed during reporting intervals.

What a Patient Investor Can Learn#

Examining Prem Watsa’s observable Form 13F activity during Q3 2026 provides actionable structural principles for value investors:

  1. High Concentration Strategy: Conviction investing requires maintaining heavy capital weightings in top ideas rather than diluting portfolio focus across minor positions. Allocating 89.7% of reported equity value across ten holdings demonstrates commitment to high-conviction security selection.
  2. Capital Recycling Within Favored Sectors: When superior scale or asset opportunities surface in a favored industry, disciplined managers completely exit long-held positions (selling $568.5 million of Orla Mining) to fund larger allocations (buying $649.1 million of Equinox Gold).
  3. Disciplined Liquidation at Extended Valuations: Watsa demonstrates a firm willingness to completely liquidate defensive blue-chip equities (such as Johnson & Johnson) when market prices decouple from conservative owner-earnings intrinsic valuations.

Key Numbers#

  • Reported US Equity Portfolio Size: $2.65 billion across 34 positions.
  • Top 10 Holdings Concentration: 89.7% of total reported value.
  • Quarterly Portfolio Turnover: 22.3% (~$699.3M bought / ~$589.7M sold).
  • Largest Position Added: Equinox Gold Corp. (EQX) at $649.1M (24.5% of total portfolio).
  • Largest Position Exited: Orla Mining Ltd. (ORLA), completely sold out (formerly ~$568.5M).
  • 10-Year Clone CAGR: 1.5% vs. SPY CAGR of 13.9%.

Limits of Form 13F & Regulatory Disclaimer#

Form 13F reports reflect only US long equity holdings as of September 30, 2026, filed up to 45 days after quarter-end. Filings exclude short positions, cash holdings, fixed income, derivative options, non-US primary equity listings, and any transactions executed after September 30, 2026.

This analysis is published strictly by DeepValues Research for educational and informational research purposes. It does not constitute individual financial, legal, tax, or investment advice.

Watch

Source links

Watch & listen

Company research

Research text CC BY 4.0, cite as: DeepValues Research, Prem Watsa’s Q3 2026 13F Portfolio Analysis: Fairfax Financial Holdings’ Strategic Shifts, https://research.deepvalues.ai/insights/2026-11-20-prem-watsa-q3-2026-13f-portfolio-research/

Weekly email

Margin of Safety Weekly

Every Saturday: the market's temperature, what the great investors bought and sold (13F filings), the week's new research, and our videos and podcasts — no account needed.

Send me the DeepValues Margin of Safety Weekly, one email every Saturday. I can unsubscribe at any time. Information only, not investment advice. Privacy

Go further

Run this analysis on any stock in 2 minutes

Deep Value Intelligence, the multi-agent AI analyst behind this report, writes the same report for any listed company on demand.

Open Deep Value Intelligence

Track 300+ stocks in the DeepValues app

Stances, intrinsic value and the latest reports, on your phone.

Developers: stances and reports via the API

The fundamentals, intrinsic values, stances and report links behind these pages, as JSON.

API docs

Discuss